Entospletinib dimesylate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 125471

CAS#: 1648797-46-9 (dimesylate)

Description: Entospletinib, also known as GS-9973, is a highly selective and orally efficacious Syk inhibitor which is currently undergoing clinical evaluation for autoimmune and oncology indications. In Phase II clinical trials, Entospletinib demonstrates clinical activity in subjects with relapsed or refractory CLL with acceptable toxicity.

Chemical Structure

img
Entospletinib dimesylate
CAS# 1648797-46-9 (dimesylate)
Instruction

Theoretical Analysis

MedKoo Cat#: 125471
Name: Entospletinib dimesylate
CAS#: 1648797-46-9 (dimesylate)
Chemical Formula: C25H29N7O7S2
Exact Mass: 603.16
Molecular Weight: 603.670
Elemental Analysis: C, 49.74; H, 4.84; N, 16.24; O, 18.55; S, 10.62

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 1648797-46-9 (dimesylate)   1229208-44-9 (free base)  

Synonym: Entospletinib dimesylate; 4N0Q3I064C; UNII-4N0Q3I064C; 1648797-46-9

IUPAC/Chemical Name: 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine dimethanesulfonate

InChi Key: WVOJPPFIOABHAB-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H21N7O.2CH4O3S/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29;2*1-5(2,3)4/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27);2*1H3,(H,2,3,4)

SMILES Code: CS(O)(=O)=O.CS(O)(=O)=O.C1CN(CCO1)C2=CC=C(NC3=NC(=CN4C=CN=C34)C5=CC=C6C=NNC6=C5)C=C2

Appearance: To be determined

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 603.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Walker AR, Byrd JC, Blachly JS, Bhatnagar B, Mims AS, Orwick S, Lin TL, Crosswell HE, Zhang D, Minden MD, Munugalavadla V, Long L, Liu J, Pan Y, Oellerich T, Serve H, Rao AV, Blum WG. Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression. Clin Cancer Res. 2020 Nov 15;26(22):5852-5859. doi: 10.1158/1078-0432.CCR-20-1064. Epub 2020 Aug 20. PMID: 32820015.


2: Kittai AS, Best S, Thurlow B, Lam V, Hashiguchi T, Goodyear S, Persky DO, Okada C, Park B, Spurgeon SE, Danilov AV. Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies. Haematologica. 2021 Jul 1;106(7):2022-2025. doi: 10.3324/haematol.2020.270298. PMID: 33504141; PMCID: PMC8252925.


3: Loftus JP, Yahiaoui A, Brown PA, Niswander LM, Bagashev A, Wang M, Schauf A, Tannheimer S, Tasian SK. Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia. Haematologica. 2021 Apr 1;106(4):1067-1078. doi: 10.3324/haematol.2019.241729. PMID: 32414848; PMCID: PMC8018117.


4: Sharman J, Di Paolo J. Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib. Ther Adv Hematol. 2016 Jun;7(3):157-70. doi: 10.1177/2040620716636542. Epub 2016 Mar 17. PMID: 27247756; PMCID: PMC4872176.


5: Duong VH, Ruppert AS, Mims AS, Borate U, Stein EM, Baer MR, Stock W, Kovacsovics T, Blum W, Arellano ML, Schiller GJ, Olin RL, Foran JM, Litzow MR, Lin TL, Patel PA, Foster MC, Redner RL, Al-Mansour Z, Cogle CR, Swords RT, Collins RH, Vergilio JA, Heerema NA, Rosenberg L, Yocum AO, Marcus S, Chen T, Druggan F, Stefanos M, Gana TJ, Shoben AB, Druker BJ, Burd A, Byrd JC, Levine RL, Boyiadzis MM. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. Cancer. 2023 Aug 1;129(15):2308-2320. doi: 10.1002/cncr.34780. Epub 2023 Apr 20. PMID: 37078412.


6: Qu C, Zheng D, Li S, Liu Y, Lidofsky A, Holmes JA, Chen J, He L, Wei L, Liao Y, Yuan H, Jin Q, Lin Z, Hu Q, Jiang Y, Tu M, Chen X, Li W, Lin W, Fuchs BC, Chung RT, Hong J. Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis. Hepatology. 2018 Sep;68(3):1125-1139. doi: 10.1002/hep.29881. Epub 2018 May 21. PMID: 29537660; PMCID: PMC6138581.


7: Tang S, Yu Q, Ding C. Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases. Expert Opin Investig Drugs. 2022 Mar;31(3):291-303. doi: 10.1080/13543784.2022.2040014. Epub 2022 Feb 18. PMID: 35130124.


8: Poe JC, Jia W, Di Paolo JA, Reyes NJ, Kim JY, Su H, Sundy JS, Cardones AR, Perez VL, Chen BJ, Chao NJ, Cardona DM, Saban DR, Sarantopoulos S. SYK inhibitor entospletinib prevents ocular and skin GVHD in mice. JCI Insight. 2018 Oct 4;3(19):e122430. doi: 10.1172/jci.insight.122430. PMID: 30282825; PMCID: PMC6237454.


9: Awan FT, Thirman MJ, Patel-Donnelly D, Assouline S, Rao AV, Ye W, Hill B, Sharman JP. Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. Leuk Lymphoma. 2019 Aug;60(8):1972-1977. doi: 10.1080/10428194.2018.1562180. Epub 2019 Jan 11. PMID: 30633573.


10: Cooper N, Ghanima W, Hill QA, Nicolson PL, Markovtsov V, Kessler C. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib. Platelets. 2023 Dec;34(1):2131751. doi: 10.1080/09537104.2022.2131751. Epub 2022 Nov 4. PMID: 36331249.


11: Lam V, Best S, Kittai A, Orand K, Spurgeon SE, Liu T, Danilov AV. Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol. 2022 Feb;88(2):836-841. doi: 10.1111/bcp.14962. Epub 2021 Jul 19. PMID: 34196037.


12: Jorda R, Krajčovičová S, Králová P, Soural M, Kryštof V. Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome. Eur J Med Chem. 2020 Oct 15;204:112636. doi: 10.1016/j.ejmech.2020.112636. Epub 2020 Jul 19. PMID: 32731189.


13: Ramanathan S, Di Paolo JA, Jin F, Shao L, Sharma S, Robeson M, Kearney BP. Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers. Clin Drug Investig. 2017 Feb;37(2):195-205. doi: 10.1007/s40261-016-0476-x. PMID: 27785737; PMCID: PMC5250654.


14: Andorsky DJ, Kolibaba KS, Assouline S, Forero-Torres A, Jones V, Klein LM, Patel-Donnelly D, Smith M, Ye W, Shi W, Yasenchak CA, Sharman JP. An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2019 Jan;184(2):215-222. doi: 10.1111/bjh.15552. Epub 2018 Sep 5. PMID: 30183069; PMCID: PMC6585960.


15: Kutsch N, Pallasch C, Tausch E, Böhme V, Ritgen M, Liersch R, Wacker A, Jacobs G, Trappe RU, Dreger P, Fischer K, Fink AM, Stilgenbauer S, Zhai S, Li B, Jürgensmeier JM, Rajakumaraswamy N, Bhargava P, Hallek M, Eichhorst BF. Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. Hemasphere. 2022 Mar 8;6(4):e692. doi: 10.1097/HS9.0000000000000692. PMID: 35284802; PMCID: PMC8906452.


16: Narayanan S, Wu ZX, Wang JQ, Ma H, Acharekar N, Koya J, Yoganathan S, Fang S, Chen ZS, Pan Y. The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance. Int J Biol Sci. 2021 Jun 22;17(10):2652-2665. doi: 10.7150/ijbs.61229. PMID: 34326700; PMCID: PMC8315011.


17: Kong W, Sender S, Perez SV, Sekora A, Ruetgen B, Junghanss C, Nolte I, Murua Escobar H. Pan- and Isoform-specific Inhibition of the Bromodomain and Extra- terminal Proteins and Evaluation of Synergistic Potential With Entospletinib in Canine Lymphoma. Anticancer Res. 2020 Jul;40(7):3781-3792. doi: 10.21873/anticanres.14367. PMID: 32620617.


18: Burke JM, Shustov A, Essell J, Patel-Donnelly D, Yang J, Chen R, Ye W, Shi W, Assouline S, Sharman J. An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331. doi: 10.1016/j.clml.2018.05.022. Epub 2018 Jun 6. PMID: 29934062; PMCID: PMC6857170.


19: Sender S, Sekora A, Villa Perez S, Chabanovska O, Becker A, Ngezahayo A, Junghanss C, Murua Escobar H. Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib. Int J Mol Sci. 2021 Jan 8;22(2):592. doi: 10.3390/ijms22020592. PMID: 33435587; PMCID: PMC7827334.


20: Yoshimoto T, Hayashi T, Kondo T, Kittaka M, Reichenberger EJ, Ueki Y. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model. J Bone Miner Res. 2018 Aug;33(8):1513-1519. doi: 10.1002/jbmr.3449. Epub 2018 May 22. PMID: 29669173; PMCID: PMC6351076.